 TransCode Therapeutics Inc NASDAQ: RNAZ has received a Fast-Track Small Business Innovation Research SBIR grant from the NIH to support developing TTX-MC138. TTX-MC138 is TransCodes lead therapeutic candidate for the treatment of metastatic solid tumors. 